Clinical Trial

Phase 4 Multicenter, Open-label Study on Efficacy and Safety of Apremilast in Moderate-to-severe Psoriasis

Name: Phase 4 Multicenter, Open-label Study on Efficacy and Safety of Apremilast in Moderate-to-severe Psoriasis — clinical trial record (NCT07190391)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting

View on ClinicalTrials.gov →

Summary

This study aims to evaluate the efficacy and safety of Apremilast tablets in patients with psoriasis over 32 weeks, through a multicenter, single-arm, open-label, phase 4 clinical trial.

Trial Details

NCT Number	NCT07190391
Lead Sponsor	Daewoong Pharmaceutical Co. LTD.
Conditions	Psoriasis
Enrollment	425 participants
Start Date	2025-09-30
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-10-31 (estimated)
Updated on ClinicalTrials.gov	2025-09-24